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Abstract
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFT) remains the gold 
standard for a definitive diagnosis of Alzheimer’s disease (AD). Nowadays, the in vivo diagnosis of AD is greatly aided by 
both cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers. Although highly accurate, their broad 
implementation is restricted by high cost, limited accessibility and invasiveness. We recently developed a high-performance, 
ultrasensitive immunoassay for the quantification of tau phosphorylated at threonine-181 (p-tau181) in plasma, which 
identifies AD pathophysiology with high accuracy. However, it remains unclear whether plasma p-tau181, measured years 
before the death, can predict the eventual neuropathological confirmation of AD, and successfully discriminates AD from 
non-AD dementia pathologies. We studied a unique cohort of 115 individuals with longitudinal blood collections with 
clinical evaluation at 8, 4 and 2 years prior to neuropathological assessment at death. The results demonstrate that plasma 
p-tau181 associates better with AD neuropathology and Braak staging than a clinical diagnosis 8 years before post-mortem. 
Moreover, while all patients had a diagnosis of AD dementia during life, plasma p-tau181 proved to discriminate AD from 
non-AD pathologies with high accuracy (AUC = 97.4%, 95% CI = 94.1–100%) even 8 years before death. Additionally, the 
longitudinal trajectory of plasma p-tau181 was assessed in all patients. We found that the main increases in plasma p-tau181 
occurred between 8 and 4 years prior to death in patients with AD neuropathology and later plateauing. In contrast, non-AD 
pathologies and controls exhibited minor, albeit significant, increases in p-tau181 up until death. Overall, our study demon-
strates that plasma p-tau181 is highly predictive and specific of AD neuropathology years before post-mortem examination. 
These data add further support for the use of plasma p-tau181 to aid clinical management in primary care and recruitment 
for clinical trials.
Keywords Alzheimer’s disease · Neuropathology · Braak · Blood biomarkers · p-tau181
Introduction
Alzheimer’s disease (AD) is the most prevalent cause of 
dementia, accounting for 50–60% of the 50 million reported 
cases worldwide, which is expected to triple by 2050 [25]. 
A definitive diagnosis of AD remains to be only possible via 
neuropathological examination that demonstrates the pres-
ence of the classical disease hallmarks, namely amyloid-β 
(Aβ) plaques together with tau neurofibrillary tangles (NFT) 
[6, 14]. However, increasingly, clinical assessment of AD is 
now being aided by neuropathologically validated biomark-
ers that reflect Aβ and tau pathologies which have led to 
the improved accuracy in diagnosing AD during life [9, 13, 
Kaj Blennow and Nicholas J. Ashton are senior authors and 
contributed equally.
Juan Lantero Rodriguez and Thomas K. Karikari are first authors 
and contributed equally.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-020-02195 -x) contains 
supplementary material, which is available to authorized users.
 * Nicholas J. Ashton 
 nicholas.ashton@gu.se
Extended author information available on the last page of the article
268 Acta Neuropathologica (2020) 140:267–278
1 3
20]. The importance of biological markers has been empha-
sised in the recent National Institute of Aging and Alzheimer 
Association (NIA-AA) Research Framework [13]. In this 
framework, AD is defined as a biological construct, docu-
mented by post-mortem examination or in vivo by biomark-
ers, and not as a clinical syndrome. Therefore, the term AD 
is applied whenever there is biomarker evidence of Aβ and 
tau pathology. There are two main types of biomarkers for 
AD, that is, neuroimaging and fluid biomarkers. Neuroim-
aging biomarkers include in vivo positron emission tomog-
raphy (PET) using ligands specific for fibrillar Aβ [3] and 
paired-helical filament tau [17, 29]. Regarding the fluid bio-
markers, the triad of cerebrospinal fluid (CSF) biomarkers, 
broadly referred as “core AD biomarkers”, are widely used 
in both clinical and research settings. They comprise Aβ42 
(or the Aβ 42/40 ratio), phosphorylated tau181 (p-tau181) 
and total tau (t-tau), which reflect Aβ pathology, tau pathol-
ogy and neuronal injury, respectively [21].
Despite their high specificity and sensitivity in detect-
ing AD pathophysiology, both CSF and imaging biomarkers 
present certain limitations, e.g. perceived invasiveness or 
complexity attached to a lumbar puncture or limited access 
to and high costs for molecular imaging, which restrict the 
use of these biomarkers to specialised centres [21]. There-
fore, a blood biomarker that reliably reflects cerebral Aβ 
and tau pathologies has huge potential as a scalable test for 
primary care and frequent disease monitoring in clinical and 
therapeutic settings. In recent years, numerous promising 
studies have explored the potential of blood biomarkers to 
provide information on cerebral pathology. Mass spectrom-
etry [22, 28] and automated immunoassays [23] measuring 
Aβ species have proven highly accurate,however, the con-
siderable peripheral expression of Aβ remains to be a sig-
nificant cofounder for these assays, making the fold change 
in Aβ42/40 ratio in amyloid PET-positive individuals much 
less pronounced in plasma than in CSF [28]. On the other 
hand, blood immunoassays targeting tau species, specifically 
tau fragments phosphorylated at threonine 181, have shown 
promising results, proving to be reliable tools for AD diag-
nosis and correlating well with in vivo assessments of Aβ 
and tau pathologies [15, 16, 32].
To our knowledge, and despite the very promising results 
in blood p-tau181, all studies conducted so far have mainly 
focused on research cohorts accurately characterised by CSF 
or PET biomarkers. Some of these studies have also vali-
dated their results in a subset of pathologically confirmed 
cases [32] but it is unclear if plasma p-tau181, determined 
years before death, can predict the eventual neuropathologi-
cal diagnosis of AD. Therefore, the main aim of this study 
was to investigate (1) if plasma p-tau181 specifically reflects 
AD pathology in neuropathologically confirmed cases, (2) if 
plasma p-tau181 would inform on a more accurate diagnosis 
of AD and highlight dementia of a non-AD type at the time 
of clinical assessment, and (3) if the longitudinal trajectories 
of plasma p-tau181 are different between neuropathologi-
cally confirmed AD patients, non-AD patients and controls. 
For this purpose, we measured plasma p-tau181 in a longi-
tudinal cohort comprising cognitively unimpaired controls 
and participants with the clinical diagnosis of mild cogni-
tive impairment (MCI) and AD dementia. At post-mortem, 
each patient was re-classified into control, AD and non-AD 
dementia based on a detailed neuropathological assessment.
Materials and methods
Study participants and design
The current study included 115 individuals selected from the 
Maudsley and King’s Healthcare Partners Dementia Case 
Register (DCR) [12], which incorporates the Alzheimer’s 
Research UK (ARUK) cohort [11]. To be included in the 
present study, individuals must have completed ≥ 1 blood 
and clinical assessment via the DCR biomarker program 
and subsequently received a post-mortem neuropathological 
assessment through brain donation to the Medical Research 
Council (MRC) London Neurodegenerative Diseases Brain 
Bank, Institute of Psychiatry, King’s College London (which 
includes donation via the Brains for Dementia Research 
(BDR) program) (Fig. 1a). The clinical data and plasma 
samples from DCR were matched to post-mortem records 
by the co-authors and are an extension of our previously 
reported cohort [2].
Plasma collections or “timepoints” were specifically 
selected on the basis of time (in years) to the recorded date of 
post-mortem (Fig. 1b); timepoint 1 = 7.88 years (SD = 1.15, 
range = 6.33–9.43), timepoint 2 = 4.15 years (SD = 0.91, 
range = 2.90–6.05) and timepoint 3 = 2.08 (SD = 0.70, 
range = 0.86–3.21). Of the 115 patients included, a total of 
83 individuals had plasma for all three timepoints, 17 indi-
viduals had two timepoints and 15 individuals with only 
one timepoint were available. At each timepoint, the clinical 
diagnosis of probable AD (AD dementia) was made accord-
ing to Diagnostic and Statistical Manual for Mental Diag-
nosis, fourth edition and National Institute of Neurological, 
Communicative Disorders and Stroke–Alzheimer’s disease 
and Related Disorders Association (NINCDS–ADRDA) 
clinical criteria. Mild cognitive impairment (MCI) was 
defined according to Petersen criteria [12]. Standardized 
clinical assessments included the informant interview for 
diagnosis and the Mini-Mental State Examination (MMSE). 
Cognitively unimpaired (CU) individuals were either 
spouses of cases or recruited though primary care registers, 
all had MMSE > 26. The human biological samples were 
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sourced ethically, and their research use was in accordance 
with the terms of the informed consent.
Plasma p‑tau181 measurement by single molecule 
array (Simoa)
All participants from the DCR were required to fast for at 
least 2 h prior to medical assessment. Venous blood was 
drawn and collected into sodium ethylenediaminetetraacetic 
acid (EDTA)-containing tubes. Within 2 h of collection, 
samples were centrifuged (8 min at 2000 × g at 4 °C) and 
stored at − 80 °C. Plasma p-tau181 concentration was meas-
ured using an ultrasensitive in-house single molecule array 
(Simoa) assay developed at the Clinical Neurochemistry 
Laboratory, Department of Psychiatry and Neurochemistry, 
University of Gothenburg, Sweden [16], on the HD-X plat-
form (Quanterix, Billerica, MA, USA). In brief, the plasma 
p-tau181 Simoa assay is comprised of paramagnetic beads 
coupled with a mouse monoclonal capture antibody specifi-
cally targeting phosphorylated threonine 181 (AT270, Invit-
rogen) and biotinylated mouse monoclonal detector antibody 
directed against the N-terminal region of tau (Tau12, Bio-
Legend). Full-length recombinant tau-441 phosphorylated 
in vitro by glycogen synthase kinase 3β (#TO8-50FN, Sig-
nalChem) was used as the calibrator. Further details about 
the assay and validation performance have been previously 
described [16]. Immediately before analysis, plasma samples 
were thawed, vortexed (2000 rpm) and centrifuged (10 min 
at 4000 × g at RT) and then diluted twofold with Tau2.0 
buffer (Quanterix, Billerica, MA, USA). Plasma samples 
were randomised and analysed using identical batches of 
reagents. Plasma p-tau181 data were collected over three 
analytical runs, and all samples measured above the lower 
limit of quantification set for the assay (1.0 pg/mL). As a 
measure of assay precision, two quality control (QC) plasma 
samples were analysed in duplicate at the start and end of 
each run. The within- and between-run coefficients of vari-
ation for both QC samples were < 10%.
Fig. 1  Study design. a The study design and timeline of sample col-
lection, subsequent brain donation and plasma p-tau181 measure-
ments. The current study included a total of 115 individuals from the 
Maudsley and King’s Healthcare Partners Dementia Case Register 
(DCR) and Alzheimer’s Research UK (ARUK) cohorts, which under-
went multiple clinical examinations between 2001 and 2012. To be 
included in the present study, individuals must have completed > 1 
blood and clinical assessment via the DCR cohort and separately, a 
neuropathological assessment from the Medical Research Council 
(MRC) London Neurodegenerative Diseases Brain. Stored plasma 
samples were analysed for p-tau181 at clinical neurochemistry labo-
ratory, Sweden. Plasma timepoints were specifically selected from 
each individual based on the time (in years) from the recorded date 
of post-mortem (b); timepoint 1 = 7.88 mean years (SD = 1.15, 
range = 6.33–9.43), timepoint 2 = 4.15 mean years (SD = 0.91, 
range = 2.90–6.05) and timepoint 3 = 2.08 mean years (SD = 0.70, 
range = 0.86–3.21)
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Neuropathological diagnosis
Consent for autopsy, neuropathological assessment and 
research was obtained for all cases and the study was car-
ried out under the ethical approval of the tissue bank. Block 
taking and neuropathological assessment were performed 
according to the standard criteria for the diagnosis of neu-
rodegenerative disease. Assessment included Braak staging 
for NFT [7] and reporting of co-existing pathology such 
as cerebrovascular lesions, TAR DNA-binding protein 43 
(TDP-43), and Lewy body pathology. Control cases were 
defined as showing no more than Braak stage II, age-related 
pathology.
Statistical analysis
SPSS (IBM, Armonk, NY) and the R programming language 
(version 3.4.3) were used for statistical analysis and Graph 
Pad PRISM for visualisation. Associations between continu-
ous variables were tested with Spearman’s rank-order corre-
lation. Group differences were assessed with Mann–Whitney 
test or one-way Kruskal–Wallis test by ranks, with post hoc 
Dunn’s test where appropriate. To measure the specificity 
and sensitivity of the p-tau181 test, we calculated the area 
under the curve (AUC) of the receiver operating character-
istics (ROC) using the ‘AUC’ package for R. A repeated 
measures one-way ANOVA with a Tukey’s post hoc test, 
adjusted for age, was used to demonstrate the trajectories of 
p-tau181 over time.
Results
Participant characteristics and the effect of age 
and sex on plasma p‑tau
One hundred and fifteen participants were included in this 
study (111 included at timepoint 1 and four additional par-
ticipants added at timepoint 2). Table 1 describes the demo-
graphical characteristics of the cohort categorised by clinical 
diagnosis and then by neuropathological diagnosis.
We first examined the cohort based on clinical diagnoses 
assigned by a clinical examination at each timepoint. There 
were no significant differences in age or sex between the 
groups at any timepoint throughout the study. As expected, a 
significant decrease in cognitive performance (MMSE) was 
observed in AD dementia patients as compared to MCI and 
CU at all timepoints (P < 0.0001). No differences in MMSE 
were observed between CU and MCI. Next, we assessed 
the demographic variables based on neuropathological diag-
nosis. Once more, at each timepoint, the neuropathologi-
cal groups did not differ significantly regarding age or sex. 
The AD pathology group had a significantly lower MMSE 
than controls at each timepoint (timepoint 1, P < 0.0001; 
timepoint 2, P = 0.001; timepoint 3, P < 0.0001). The non-
AD group had significantly lower MMSE than controls at 
timepoint 1 (P = 0.013) and timepoint 2 (P = 0.015) but not 
at timepoint 3. A statistically significant difference in MMSE 
score between non-AD and AD was only observed at time-
point 3 (P < 0.0001).
In the whole cohort, there was significant but weak 
association between age and plasma p-tau181 at all time-
points (r = 0.251–0.302, P < 0.050). No differences in sex 
were observed after a correction for age, although the mean 
p-tau181 concentration was consistently higher in females 
at all timepoints.
Plasma p‑tau181 associates 
with post‑mortem‑confirmed AD pathology
We first tested whether plasma p-tau181 differed between 
clinical syndromes (Fig. 2a). At all three timepoints studied, 
plasma p-tau181 was significantly higher in AD dementia 
syndrome as compared to CU individuals (timepoint 1, 
P = 0.001; timepoint 2, P < 0.0001; timepoint 3, P < 0.0001), 
but not compared to MCI (Fig. 2a). However, only 75% of 
the clinically diagnosed AD dementia patients exhibited AD 
pathology at post-mortem. Therefore, we next compared the 
levels of plasma p-tau181 between the three neuropatho-
logical diagnosis groups (i.e., controls, non-AD and AD; 
depicted by colour coding in Fig. 2a), regardless of their 
prior clinical diagnosis. Interestingly, we found that the AD 
pathology group had significantly higher plasma p-tau181 
as compared to the control (P < 0.0001) and non-AD pathol-
ogy groups (P < 0.0001, Fig. 2b). This increase occurred at 
all three plasma timepoints. On the contrary, no differences 
between pathologically confirmed controls and non-AD 
pathology were observed at any timepoint (Fig. 2b). Note 
that the increase in plasma p-tau181 in the AD pathology 
compared to the control group ranged between 68.5 and 
89.3%, a higher increase than that found between the clinical 
diagnosis of AD dementia syndrome and CU (47.1–59.1%). 
This favours the idea that plasma p-tau181 reflects AD 
pathology, regardless of the clinical presentation. The AD 
pathology group also included individuals with mixed 
pathology (i.e., with additional Lewy body disease and/or 
TDP-43 pathology) and excluding them from the analyses 
did not change the result.
We also tested whether plasma p-tau181 changes as a 
function of Braak stages, which scores the spread of NFT 
in the brain. Plasma p-tau181 increased in Braak stages 
V–VI as compared to Braak stages I–II at all timepoints 
(P < 0.0001, Fig. 3). At 8 years from post-mortem, plasma 
p-tau181 was significantly increased in Braak V–VI as 
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compared to III–IV (P = 0.035, Fig. 3) whereas no statisti-
cal difference was observed between Braak I–II and Braak 
III–IV. However, at later timepoints (4 and 2 years before 
post-mortem), significant increases where only observed 
between I–II and III–IV (P < 0.006) and not between III–IV 
and V–VI. Together, these results show that plasma p-tau181 
is increased in AD pathology, even years before the eventual 
pathological confirmation.
Plasma p‑tau181 predicts AD pathology 
from non‑AD pathology 8 years before post‑mortem 
irrespective of clinical diagnosis
Figure 4a shows a detailed breakdown of neuropathological 
classification of individuals at post-mortem on the x-axis and 
their corresponding plasma p-tau181 levels at timepoint 1 
(8 years before post-mortem). There was no significant dif-
ference in plasma p-tau181 between AD and all AD plus co-
pathologies (Fig. 4a) which was also observed at subsequent 
timepoints (Supplementary Fig. 1a, b, online resource). 
Additionally, there was no change in p-tau181 between 
non-AD pathologies at timepoint 1; however, significant 
increases of p-tau181 were observed in Lewy body demen-
tias as compared to other non-AD dementias at timepoints 
2 and 3 (Supplementary Fig. 1a, b, online resource) but not 
at timepoint 1.
We hypothesised that plasma p-tau181 would discrimi-
nate between AD pathology and non-AD pathology several 
years before the neuropathological confirmation. To test 
this hypothesis, we conducted a ROC analysis and dem-
onstrated that plasma p-tau181 measured 8 years prior to 
post-mortem has a high area under the curve (AUC) in 
separating AD from non-AD pathologies (AUC = 97.4%, 
95% CI = 94.1–100%) and controls (AUC = 92.1%, 95% 
CI = 82.4–100%, Fig. 4b). Similarly, a good performance 
was demonstrated in separating mixed AD pathologies from 
non-AD pathologies (AUC = 90.1%, 95% CI = 83.4–96.8%) 
and controls (AUC = 84.1%, 95% CI = 72.4–97.3%, Fig. 4c) 
8 years prior to post-mortem. The low AUC in separating 
AD from mixed AD pathologies (AUC = 57.3%) demon-
strates that plasma p-tau181 is not sensitive to the contribu-
tion of co-pathologies.
Fig. 2  Plasma p-tau181 associates with post-mortem confirmed AD 
pathology. Plasma concentrations of p-tau181 categorised by clinical 
diagnosis (a) and neuropathological diagnosis given at post-mortem 
(b). The concentrations of plasma p-tau181 are shown at three differ-
ent time points; 8 years, 4 years prior and 2 years prior to post-mor-
tem. In a, the clinical diagnosis assigned at each timepoint are given 
on the x-axis and individual data points are colour coded according 
the neuropathological diagnosis given at post-mortem to visualise the 
disparity in clinical classification given at each visitation and underly-
ing pathology uncovered at post-mortem; controls (blue), AD (red), 
non-AD (green). At timepoint 1, 111 individuals were included (con-
trol, n = 27; MCI, n = 6; AD, n = 78). At timepoint 2, 100 individuals 
were included (control, n = 24; MCI, n = 5; AD, n = 71). At timepoint 
3, 87 individuals were included (control, n = 20; MCI, n = 5; AD, 
n = 62). In b, the neuropathological diagnosis given at post-mortem is 
on the x-axis with the same colour coding as (b)
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Longitudinal trajectories of p‑tau181 are dependent 
on post‑mortem pathology
Finally, we assessed whether levels of plasma p-tau181 
longitudinally changes in patients eventually diagnosed 
with AD pathology. Patients were categorised based on 
post-mortem classification and only individuals with ≥ 2 
timepoints were included, this resulted in 100 individuals 
(controls, n = 9; AD, n = 22; mixed AD, n = 41; non-AD, 
n = 28) being included in the analysis. In a repeated meas-
ures one-way ANOVA, we found a statistically significant 
effect of time on plasma p-tau181 for AD pathology [F 
(1.56, 31.27) = 11.35, P < 0.0001], mixed AD pathology 
[F (1.67, 59.41) = 6.24, P = 0.005] and non-AD pathology 
[F (1.71, 41.83) = 14.52, P < 0.0001]. A Tukey post hoc 
analysis demonstrated that plasma p-tau181 significantly 
increased from timepoint 1 to timepoint 2 in both the AD 
pathology and AD mixed pathology groups (P < 0.0001 
and P = 0.022, respectively). However, the plasma p-tau181 
increase in the AD group was more pronounced than that of 
the AD mixed pathology group. Plasma p-tau181 was only 
significantly increased from timepoint 1 to timepoint 3 in 
the AD pathology group (P = 0.0006), although an increase 
approaching significance was also observed in the mixed 
AD pathology group (P = 0.060, Fig. 5). Interestingly, while 
no significant change in plasma p-tau181 concentration was 
observed between timepoints 2 and 3 for the AD pathol-
ogy or AD mixed pathology groups, a mild but significant 
increase was observed for both the control (P = 0.049) and 
non-AD pathology groups (P = 0.002). Together, these 
results suggest that individuals who develop AD pathology 
undergo an increase of plasma p-tau181 several years before 
the final neuropathological diagnosis. Interestingly, Lewy 
body dementias demonstrated a similar pattern to AD and 
mixed AD pathologies where an approaching significant 
increase (P = 0.065) was observed between timepoints 1 and 
2, which plateaued at timepoint 3 (Supplementary Fig. 2, 
online resource).
Discussion
In a longitudinal cohort with neuropathological characteri-
sation, we demonstrated that plasma p-tau181 predicts AD 
pathology at least 8 years prior to death and neuropathologi-
cal confirmation, and accurately discriminates between AD 
and non-AD pathologies. Our data suggest, an individual 
clinically diagnosed of AD dementia syndrome but with 
low concentrations of plasma p-tau181 is more indicative 
of non-AD than AD pathology. We have also demonstrated 
Fig. 3  Plasma p-tau181 associ-
ates Braak staging. Plasma 
concentrations of p-tau181 
categorised by Braak staging 
assigned at post-mortem (Braak 
I–II, Transentorhinal; Braak 
III–IV, Limbic; Braak V–VI, 
Isocortical). The concentrations 
of plasma p-tau181 are shown 
at three different time points; 
8 years, 4 years prior and 
2 years prior to post-mortem
274 Acta Neuropathologica (2020) 140:267–278
1 3
that plasma p-tau181 increases over time in cases with AD 
pathology, most likely in parallel to neurofibrillary tan-
gle neurodegeneration (as shown by Braak stages). This 
increase, however, plateaus at the very advanced stages of 
the disease. Altogether, our results support the idea of using 
plasma p-tau181 as a biomarker of AD at the clinical setting 
or in clinical trials when CSF and/or PET biomarkers are not 
available. Alternatively, plasma p-tau181 could be used as a 
pre-screening tool to select those patients who would further 
undergo lumbar puncture or PET imaging.
Fig. 4  Plasma p-tau181 predicts AD pathology from non-AD pathol-
ogy 8 years before post-mortem irrespective of clinical diagnosis. a 
A detailed breakdown of neuropathological classification of indi-
viduals at post-mortem on the x-axis and their corresponding plasma 
p-tau181 at timepoint 1 (8  years before post-mortem). ROC curves 
demonstrate the ability of plasma p-tau181 to separate AD (b) and 
mixed AD (c) from other neuropathological confirmed pathologies 
8 years prior to post-mortem
Fig. 5  Longitudinal trajecto-
ries of p-tau181 are dependent 
on post-mortem pathology. A 
repeated measures one-way 
ANOVA demonstrated the 
longitudinal changes of plasma 
p-tau181 in AD, mixed AD, 
non-AD and controls confirmed 
at post-mortem
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As the field of fluid biomarkers in neurodegeneration 
moves towards targeted analysis in blood, several novel 
assays have been developed. Assays targeting Aβ [22, 23, 
28], t-tau [8, 24] and NfL [2, 5, 18] in blood have demon-
strated promising results. However, they are compromised 
by either substantial peripheral expression of the targeted 
protein [26], poor correlations with CSF measures of the 
same protein [19] and large overlaps between the neuro-
degenerative disease groups [1, 10]. These limitations may 
make the use of these biomarkers to diagnose and/or predict 
the development of AD pathology more difficult at the indi-
vidual level. A major breakthrough has been the develop-
ment of assays to sensitively measure plasma p-tau181 by 
us and other groups [15, 16, 32]. In contrast to the aforemen-
tioned biomarkers, p-tau181 can be robustly measured in 
plasma, is highly specific for AD, provides high diagnostic 
accuracy for discriminating AD and non-AD dementia, and 
it also finely discriminates between Aβ-positive CU older 
adults from those that are Aβ-negative. Furthermore, plasma 
p-tau181 correlates with CSF p-tau181 and identifies tau 
PET uptake, suggesting that p-tau181 found in plasma is 
predominately derived from the central nervous system and 
not from a peripheral source.
To the best of our knowledge, this is the first study of 
longitudinal plasma p-tau181 with a confirmed neuropatho-
logical diagnosis. Although the clinical diagnosis of AD by 
an expert neurologist is very reliable, it is not rare to find 
discordances between the clinical and the final pathologi-
cal diagnosis [4]. In our study, we initially demonstrated a 
significant increase in plasma p-tau181 in the AD demen-
tia syndrome group compared to the CU groups. However, 
there was a large overlap in plasma p-tau181 with the control 
group likely owing to the lack of CSF and PET characteri-
sation in this cohort. Remarkably, when this comparison 
was performed between pathologically defined groups, the 
magnitude of the differences between the AD pathology 
and control group was considerably higher. These results 
indicate that plasma p-tau181 is specific for AD pathology, 
irrespective of whether the clinical presentation resembles 
a typical AD dementia or another type of dementia. We fur-
ther confirmed this idea by the fact that plasma p-tau181 
discriminates AD pathology from non-AD pathology with 
an AUC of 97.4% 8 years prior to post-mortem, which is 
of equivalent performance to the well-established CSF AD 
core biomarkers (Aβ42, p-tau and t-tau) or Aβ and Tau PET. 
Our study to some extent mimics a still common situation 
in several non-specialised clinics, where these CSF or PET 
biomarkers are not available. Our results open the possi-
bility of routinely using plasma p-tau181 to improve the 
confidence in administering symptomatic treatment (e.g. 
acetylcholinesterase inhibitors or memantine), or better 
inform on patient management. Also, it may be used in both 
clinical practice and clinical trials as a first screening tool 
that may be followed, if needed, by CSF or PET biomarker 
confirmation.
In addition to comparing plasma p-tau181 in clinical 
and neuropathological classifications, we also examined 
the relationship of plasma p-tau181 with Braak staging. 
We observed that a significant increase of plasma p-tau181 
occurred between Braak I–II (Transentorhinal) and V–VI 
(Isocortical) at all timepoints. We also observed, at 8 years 
prior to post-mortem, a significant increase of plasma 
p-tau181 between Braak stages III–IV (Limbic) and V–VI 
but this was not apparent at later timepoints. Instead, 4 years 
and 2 years antemortem, the significant differences occurred 
between Braak stages I–II and III–IV. Moreover, plasma 
p-tau181 concentrations in individuals classified as Braak 
stage III–IV followed an increasing mean trend across all 
three timepoints. In contrast, no mean change in Braak stages 
I–II was observed and individuals that reached a higher 
degree of tau pathology, that is Isocortical Braak V–VI, 
began to plateau after initial significant increase between 
8 and 4 years antemortem. These trajectories are probably 
parallel to that of Aβ pathology, which also plateaus at more 
advanced stages. In fact, plasma p-tau181 highly correlates 
with Aβ PET [15, 16, 32]. These results suggest that plasma 
p-tau181 is a good diagnostic marker in both early and late 
stages of the disease. However, plasma p-tau181 may only 
be useful as a biomarker of the burden of the disease at early 
stages, when its levels follow an increasing trajectory, rather 
than at late stages, when the levels plateau.
Another novel contribution of our study is that we dem-
onstrate that the trajectories of plasma p-tau181 change 
over several years in patients with AD. The availability of 
repeated plasma samples over the course of a decade allowed 
us to define this trajectory. Interestingly, we found that the 
main increase in plasma p-tau181 in the AD pathology 
group occurred from timepoint 1 (8 years prior to post-mor-
tem) and timepoint 2 (4 years prior to post-mortem). How-
ever, between timepoint 2 (4 years prior to post-mortem) 
and timepoint 3 (2 years prior to post-mortem) p-tau181 
began to plateau. This suggests that the main increase in 
plasma p-tau181 occurs several years before there is overt 
AD pathology. In the case of AD with contaminate pathol-
ogy, this increase was less steep but still significant and fol-
lowing the same trajectory as AD pathology. These find-
ings are consistent with the longitudinal studies showing 
that CSF p-tau or t-tau does not increase, or it may even 
decrease, in advanced stages of the disease, which may indi-
cate a deceleration in neurodegeneration due to substantial 
neuronal loss [31]. This hypothesis has also gained support 
from recent stable isotope labelling kinetics (SILK) studies 
that track the turnover of tau in the human central nervous 
system (CNS) [27]. In contrast to the AD pathology groups, 
we observed a slight but statistically significant increase of 
plasma p-tau181 between timepoints 2 and 3 for the non-AD 
276 Acta Neuropathologica (2020) 140:267–278
1 3
dementia and control groups. This slight increase cannot 
be attributed to underlying Aβ pathology, due to the neu-
ropathological report, but there may be other factors that 
have an effect on p-tau181, such as ageing or co-pathology 
(TDP-43, α-synuclein).
Our study has some limitations. First, the availability of 
CSF or PET biomarker data would have allowed us to com-
pare the predictive value of plasma p-tau181 with accepted 
gold-standard biomarkers for AD. Second, the number of CU 
participants that eventually were pathologically diagnosed 
as AD was low and, therefore, we could not test whether 
plasma p-tau181 can also predict AD pathology at early 
preclinical stages. In a similar manner, the number of MCI 
patients in this study was low and, therefore, the progres-
sion from MCI to AD dementia could not be investigated. 
Furthermore, the AD dementia patients were quite impaired 
already at the first timepoint, with an average MMSE score 
of 12. Finally, detailed Aβ pathological data, such as Thal 
staging, were not available for all cases. However, recently, 
Thal staging has been shown to not substantially contribute 
to predicting antemortem cognition as compared to neuritic 
plaque scores and Braak NFT stages [30]. The main strength 
is that we studied a very well-characterised cohort of par-
ticipants, with longitudinal samples and neuropathological 
confirmation. Furthermore, we used a very sensitive and 
robust p-tau181 assay which, importantly, can be easily set 
up in other centres and hence replicate our results.
In conclusion, our study demonstrates that plasma 
p-tau181 predicts AD pathology, even if the blood sample 
was obtained several years before the post-mortem exami-
nation. This has obvious consequences in both the design 
of clinical trials and at the routine clinical practice. Plasma 
p-tau181 could be used as a rapid and cost-effective screen-
ing tool for participant selection for therapeutic trials of AD. 
Furthermore, the high accuracy of p-tau181 in predicting 
confirmed AD neuropathology may guide clinicians in an 
accurate diagnosis of the underlying mechanism causing 
cognitive decline (AD pathology, non-AD or mixed) and, 
therefore, symptomatic treatment and patient management 
can be governed at the earliest stage with a higher degree 
of confidence.
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